Top

Endocrine

Published in:

01-11-2019 | Albiglutide | Meta-Analysis

GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials

Authors: Chuqing Cao, Shuting Yang, Zhiguang Zhou

Published in: Endocrine | Issue 2/2019

Abstract

Purpose

Some preliminary studies reported a link between GLP-1 receptor agonists (GLP-1RAs) and thyroid/pancreatic neoplasms, while its human relevance remained undetermined. The present meta-analysis was performed to collect information on cancers associated with GLP-1RAs in patients with type 2 diabetes mellitus (T2DM).

Methods

Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and ClinicalTrials.gov were extensively searched to identify randomized controlled trials that reported cancer events in T2DM patients treated with GLP-1RAs for at least 52 weeks, up to March 18, 2019. Odds ratio (OR) with 95% Confidence Interval (CI) was calculated for overall cancer (primary outcome), thyroid and pancreatic cancer.

Results

A total of 37 eligible trials were identified. The OR for overall cancer associated with GLP-1RAs was 1.03 (95% CI 0.95–1.12; p = 0.41) compared with comparators. Subgroup analyses showed that treatment with albiglutide was associated with a lower risk of overall cancer (OR 0.76 [95% CI 0.60–0.97]; p = 0.03), and no elevated risk of overall cancer was identified for other GLP-1RAs. No significant differences in the risks of thyroid nor pancreatic cancer were disclosed between GLP-1RAs and comparators.

Conclusions

This meta-analysis did not suggest any increased risk of cancers associated with GLP-1RAs use in T2DM. The reduction in the risk of overall cancer associated with albiglutide needs to be examined further.

Available only for authorised users

K.K. Tsilidis, J.C. Kasimis, D.S. Lopez, E.E. Ntzani, J.P. Ioannidis, Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350, g7607 (2015). https://doi.org/10.1136/bmj.g7607 CrossRefPubMed

S. O’Neill, L. O’Driscoll, Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes. Rev. 16(1), 1–12 (2015). https://doi.org/10.1111/obr.12229 CrossRef

X. Michelet, L. Dyck, A. Hogan, R.M. Loftus, D. Duquette, K. Wei, S. Beyaz, A. Tavakkoli, C. Foley, R. Donnelly, C. O'Farrelly, M. Raverdeau, A. Vernon, W. Pettee, D. O'Shea, B.S. Nikolajczyk, K.H.G. Mills, M.B. Brenner, D. Finlay, L. Lynch, Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat. Immunol. 19(12), 1330–1340 (2018). https://doi.org/10.1038/s41590-018-0251-7 CrossRefPubMed

C.Q. Cao, Y.F. Xiang, Z.G. Zhou, The clinical application of linagliptin in Asians. Ther. Clin. Risk Manag 11, 1409–1419 (2015). https://doi.org/10.2147/TCRM.S64402 CrossRefPubMedPubMedCentral

Y. Zhao, L. Yang, Y. Xiang, L. Liu, G. Huang, Z. Long, X. Li, R.D. Leslie, X. Wang, Z. Zhou, Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J. Clin. Endocrinol. Metab. 99(5), E876–E880 (2014). https://doi.org/10.1210/jc.2013-3633 CrossRefPubMed

L. Bjerre Knudsen, L.W. Madsen, S. Andersen, K. Almholt, A.S. de Boer, D.J. Drucker, C. Gotfredsen, F.L. Egerod, A.C. Hegelund, H. Jacobsen, S.D. Jacobsen, A.C. Moses, A.M. Molck, H.S. Nielsen, J. Nowak, H. Solberg, T.D. Thi, M. Zdravkovic, U. Moerch, Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151(4), 1473–1486 (2010). https://doi.org/10.1210/en.2009-1272 CrossRefPubMed

M. Elashoff, A.V. Matveyenko, B. Gier, R. Elashoff, P.C. Butler, Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141(1), 150–156 (2011). https://doi.org/10.1053/j.gastro.2011.02.018 CrossRefPubMedPubMedCentral

D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, P. Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg. 8(5), 336–341 (2010). https://doi.org/10.1016/j.ijsu.2010.02.007 CrossRefPubMed

D. Moher, B. Pham, A. Jones, D.J. Cook, A.R. Jadad, M. Moher, P. Tugwell, T.P. Klassen, Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352(9128), 609–613 (1998). https://doi.org/10.1016/S0140-6736(98)01085-X CrossRefPubMed

10.

A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, H.J. McQuay, Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials 17(1), 1–12 (1996)CrossRef

11.

M.C. Bunck, M. Diamant, A. Corner, B. Eliasson, J.L. Malloy, R.M. Shaginian, W. Deng, D.M. Kendall, M.R. Taskinen, U. Smith, H. Yki-Jarvinen, R.J. Heine, One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32(5), 762–768 (2009). https://doi.org/10.2337/dc08-1797 CrossRefPubMedPubMedCentral

12.

M. Diamant, L. Van Gaal, B. Guerci, S. Stranks, J. Han, J. Malloy, M.K. Boardman, M.E. Trautmann, Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2(6), 464–473 (2014). https://doi.org/10.1016/S2213-8587(14)70029-4 CrossRefPubMed

13.

B. Gallwitz, J. Guzman, F. Dotta, B. Guerci, R. Simo, B.R. Basson, A. Festa, J. Kiljanski, H. Sapin, M. Trautmann, G. Schernthaner, Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 379(9833), 2270–2278 (2012). https://doi.org/10.1016/S0140-6736(12)60479-6 CrossRefPubMed

14.

R.R. Holman, M.A. Bethel, R.J. Mentz, V.P. Thompson, Y. Lokhnygina, J.B. Buse, J.C. Chan, J. Choi, S.M. Gustavson, N. Iqbal, A.P. Maggioni, S.P. Marso, P. Ohman, N.J. Pagidipati, N. Poulter, A. Ramachandran, B. Zinman, A.F. Hernandez, E.S. Group, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377(13), 1228–1239 (2017). https://doi.org/10.1056/NEJMoa1612917 CrossRefPubMed

15.

S.A. Jabbour, J.P. Frias, E. Hardy, A. Ahmed, H. Wang, P. Ohman, C. Guja, Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. Diabetes Care 41(10), 2136–2146 (2018). https://doi.org/10.2337/dc18-0680 CrossRefPubMedPubMedCentral

16.

M. Jaiswal, C.L. Martin, M.B. Brown, B. Callaghan, J.W. Albers, E.L. Feldman, R. Pop-Busui, Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. J. Diabetes Complicat. 29(8), 1287–1294 (2015). https://doi.org/10.1016/j.jdiacomp.2015.07.013 CrossRefPubMedPubMedCentral

17.

M.A. Nauck, S. Duran, D. Kim, D. Johns, J. Northrup, A. Festa, R. Brodows, M. Trautmann, A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50(2), 259–267 (2007). https://doi.org/10.1007/s00125-006-0510-2 CrossRefPubMed

18.

M.J. Davies, R. Bergenstal, B. Bode, R.F. Kushner, A. Lewin, T.V. Skjoth, A.H. Andreasen, C.B. Jensen, R.A. DeFronzo, N.N.S. Group, Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA 314(7), 687–699 (2015). https://doi.org/10.1001/jama.2015.9676 CrossRefPubMed

19.

A. Garber, R.R. Henry, R. Ratner, P. Hale, C.T. Chang, B. Bode, L.-S. Group, Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes. Metab. 13(4), 348–356 (2011). https://doi.org/10.1111/j.1463-1326.2010.01356.x CrossRefPubMedPubMedCentral

20.

S.C. Gough, B.W. Bode, V.C. Woo, H.W. Rodbard, S. Linjawi, M. Zacho, P.D. Reiter, J.B. Buse, One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes. Metab. 17(10), 965–973 (2015). https://doi.org/10.1111/dom.12498 CrossRefPubMedPubMedCentral

21.

K. Kaku, M.F. Rasmussen, P. Clauson, Y. Seino, Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes. Metab. 12(4), 341–347 (2010). https://doi.org/10.1111/j.1463-1326.2009.01194.x CrossRefPubMed

22.

K. Kaku, A. Kiyosue, Y. Ono, T. Shiraiwa, S. Kaneko, K. Nishijima, H. Bosch-Traberg, Y. Seino, Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: a randomized, 52-week, open-label, parallel-group trial. J. Diabetes Investig. 7(1), 76–84 (2016). https://doi.org/10.1111/jdi.12367 CrossRefPubMed

23.

S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, L.S. Ravn, W.M. Steinberg, M. Stockner, B. Zinman, R.M. Bergenstal, J.B. Buse; L.S. Committee, L.T. Investigators, Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375(4), 311–322 (2016). https://doi.org/10.1056/NEJMoa1603827 CrossRefPubMedPubMedCentral

24.

M. Nauck, A. Frid, K. Hermansen, A.B. Thomsen, M. During, N. Shah, T. Tankova, I. Mitha, D.R. Matthews, Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes. Metab. 15(3), 204–212 (2013). https://doi.org/10.1111/dom.12012 CrossRefPubMed

25.

R. Pratley, M. Nauck, T. Bailey, E. Montanya, R. Cuddihy, S. Filetti, A. Garber, A.B. Thomsen, H. Hartvig, M. Davies, L.-D.-S Group, One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J. Clin. Pract. 65(4), 397–407 (2011). https://doi.org/10.1111/j.1742-1241.2011.02656.x CrossRefPubMedPubMedCentral

26.

Y. Seino, M.F. Rasmussen, T. Nishida, K. Kaku, Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr. Med. Res. Opin. 26(5), 1013–1022 (2010). https://doi.org/10.1185/03007991003672551 CrossRefPubMed

27.

B. Ahren, A. Leguizamo Dimas, P. Miossec, S. Saubadu, R. Aronson, Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 36(9), 2543–2550 (2013). https://doi.org/10.2337/dc12-2006 CrossRefPubMedPubMedCentral

28.

G.B. Bolli, M. Munteanu, S. Dotsenko, E. Niemoeller, G. Boka, Y. Wu, M. Hanefeld, Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet. Med. 31(2), 176–184 (2014). https://doi.org/10.1111/dme.12328 CrossRefPubMed

29.

M.A. Pfeffer, B. Claggett, R. Diaz, K. Dickstein, H.C. Gerstein, L.V. Kober, F.C. Lawson, L. Ping, X. Wei, E.F. Lewis, A.P. Maggioni, J.J. McMurray, J.L. Probstfield, M.C. Riddle, S.D. Solomon, J.C. Tardif, E. Investigators, Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373(23), 2247–2257 (2015). https://doi.org/10.1056/NEJMoa1509225 CrossRefPubMed

30.

M. Pinget, R. Goldenberg, E. Niemoeller, I. Muehlen-Bartmer, H. Guo, R. Aronson, Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes. Metab. 15(11), 1000–1007 (2013). https://doi.org/10.1111/dom.12121 CrossRefPubMed

31.

M.C. Riddle, R. Aronson, P. Home, M. Marre, E. Niemoeller, P. Miossec, L. Ping, J. Ye, J. Rosenstock, Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 36(9), 2489–2496 (2013). https://doi.org/10.2337/dc12-2454 CrossRefPubMedPubMedCentral

32.

J. Rosenstock, M. Hanefeld, P. Shamanna, K.W. Min, G. Boka, P. Miossec, T. Zhou, I. Muehlen-Bartmer, R.E. Ratner, Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J. Diabetes Complicat. 28(3), 386–392 (2014). https://doi.org/10.1016/j.jdiacomp.2014.01.012 CrossRefPubMed

33.

B. Ahren, L. Masmiquel, H. Kumar, M. Sargin, J.D. Karsbol, S.H. Jacobsen, F. Chow, Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 5(5), 341–354 (2017). https://doi.org/10.1016/S2213-8587(17)30092-X CrossRefPubMed

34.

K. Kaku, Y. Yamada, H. Watada, A. Abiko, T. Nishida, J. Zacho, A. Kiyosue, Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial. Diabetes Obes. Metab. 20(5), 1202–1212 (2018). https://doi.org/10.1111/dom.13218 CrossRefPubMedPubMedCentral

35.

S.P. Marso, S.C. Bain, A. Consoli, F.G. Eliaschewitz, E. Jodar, L.A. Leiter, I. Lingvay, J. Rosenstock, J. Seufert, M.L. Warren, V. Woo, O. Hansen, A.G. Holst, J. Pettersson, T. Vilsboll; S.-. Investigators, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375(19), 1834–1844 (2016). https://doi.org/10.1056/NEJMoa1607141 CrossRefPubMed

36.

B. Ahren, S.L. Johnson, M. Stewart, D.T. Cirkel, F. Yang, C. Perry, M.N. Feinglos, H.S. Group, HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 37(8), 2141–2148 (2014). https://doi.org/10.2337/dc14-0024 CrossRefPubMed

37.

A.F. Hernandez, J.B. Green, S. Janmohamed, R.B. D′Agostino Sr., C.B. Granger, N.P. Jones, L.A. Leiter, A.E. Rosenberg, K.N. Sigmon, M.C. Somerville, K.M. Thorpe, J.J.V. McMurray, S. Del Prato; c. Harmony Outcomes, investigators, Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157), 1519–1529 (2018). https://doi.org/10.1016/S0140-6736(18)32261-X CrossRefPubMed

38.

P.D. Home, P. Shamanna, M. Stewart, F. Yang, M. Miller, C. Perry, M.C. Carr, Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes. Metab. 17(2), 179–187 (2015). https://doi.org/10.1111/dom.12414 CrossRefPubMed

39.

L.A. Leiter, M.C. Carr, M. Stewart, A. Jones-Leone, R. Scott, F. Yang, Y. Handelsman, Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care 37(10), 2723–2730 (2014). https://doi.org/10.2337/dc13-2855 CrossRefPubMed

40.

L.A. Leiter, J.L. Gross, F. Chow, D. Miller, S. Johnson, B. Ahren, H.S. Group, Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks. J. Diabetes Complicat. 31(8), 1283–1285 (2017). https://doi.org/10.1016/j.jdiacomp.2017.05.010 CrossRefPubMed

41.

M.A. Nauck, M.W. Stewart, C. Perkins, A. Jones-Leone, F. Yang, C. Perry, R.R. Reinhardt, M. Rendell, Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia 59(2), 266–274 (2016). https://doi.org/10.1007/s00125-015-3795-1 CrossRefPubMed

42.

P.N. Weissman, M.C. Carr, J. Ye, D.T. Cirkel, M. Stewart, C. Perry, R. Pratley, HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia 57(12), 2475–2484 (2014). https://doi.org/10.1007/s00125-014-3360-3 CrossRefPubMed

43.

L. Blonde, J. Jendle, J. Gross, V. Woo, H. Jiang, J.L. Fahrbach, Z. Milicevic, Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 385(9982), 2057–2066 (2015). https://doi.org/10.1016/S0140-6736(15)60936-9 CrossRefPubMed

44.

F. Giorgino, M. Benroubi, J.H. Sun, A.G. Zimmermann, V. Pechtner, Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 38(12), 2241–2249 (2015). https://doi.org/10.2337/dc14-1625 CrossRefPubMed

45.

K.R. Tuttle, M.C. Lakshmanan, B. Rayner, R.S. Busch, A.G. Zimmermann, D.B. Woodward, F.T. Botros, Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 6(8), 605–617 (2018). https://doi.org/10.1016/S2213-8587(18)30104-9 CrossRefPubMed

46.

G. Umpierrez, S. Tofe Povedano, F. Perez Manghi, L. Shurzinske, V. Pechtner, Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 37(8), 2168–2176 (2014). https://doi.org/10.2337/dc13-2759 CrossRefPubMed

47.

R.S. Weinstock, B. Guerci, G. Umpierrez, M.A. Nauck, Z. Skrivanek, Z. Milicevic, Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes. Metab. 17(9), 849–858 (2015). https://doi.org/10.1111/dom.12479 CrossRefPubMedPubMedCentral

48.

C. Alves, F. Batel-Marques, A.F. Macedo, A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin. Pract. 98(2), 271–284 (2012). https://doi.org/10.1016/j.diabres.2012.09.008 CrossRefPubMed

49.

I. Martin-Lacave, R. Bernab, C. Sampedro, E. Conde, J.M. Fernandez-Santos, M.V. San Martin, A. Beato, H. Galera-Davidson, Correlation between gender and spontaneous C-cell tumors in the thyroid gland of the Wistar rat. Cell Tissue Res. 297(3), 451–457 (1999). https://doi.org/10.1007/s004410051371 CrossRefPubMed

50.

B. Gier, P.C. Butler, C.K. Lai, D. Kirakossian, M.M. DeNicola, M.W. Yeh, Glucagon like peptide-1 receptor expression in the human thyroid gland. J. Clin. Endocrinol. Metab. 97(1), 121–131 (2012). https://doi.org/10.1210/jc.2011-2407 CrossRefPubMed

51.

L. Hegedus, A.C. Moses, M. Zdravkovic, T. Le Thi, G.H. Daniels, GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J. Clin. Endocrinol. Metab. 96(3), 853–860 (2011). https://doi.org/10.1210/jc.2010-2318 CrossRefPubMed

52.

A. Noone, N. Howlader, M. Krapcho. SEER Cancer Statistics Review, 1975–2015 (National Cancer Institute, Bethesda, MD, 2018), https://seer.cancer.gov/csr/1975_2015/. Accessed 22 Oct 2018.

53.

B. Waser, A. Blank, E. Karamitopoulou, A. Perren, J.C. Reubi, Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod. Pathol. 28(3), 391–402 (2015). https://doi.org/10.1038/modpathol.2014.113 CrossRefPubMed

54.

E. Raschi, C. Piccinni, E. Poluzzi, G. Marchesini, F. De Ponti, The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol. 50(4), 569–577 (2013). https://doi.org/10.1007/s00592-011-0340-7 CrossRefPubMed

55.

A.E. Butler, M. Campbell-Thompson, T. Gurlo, D.W. Dawson, M. Atkinson, P.C. Butler, Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62(7), 2595–2604 (2013). https://doi.org/10.2337/db12-1686 CrossRefPubMedPubMedCentral

56.

J.A. Romley, D.P. Goldman, M. Solomon, D. McFadden, A.L. Peters, Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol. Ther. 14(10), 904–911 (2012). https://doi.org/10.1089/dia.2012.0075 CrossRefPubMedPubMedCentral

57.

L. Azoulay, K.B. Filion, R.W. Platt, M. Dahl, C.R. Dormuth, K.K. Clemens, M. Durand, D.N. Juurlink, L.E. Targownik, T.C. Turin, J.M. Paterson, P. Ernst; I. Canadian Network for Observational Drug Effect Studies, Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ 352, i581 (2016). https://doi.org/10.1136/bmj.i581 CrossRefPubMedPubMedCentral

58.

D. Abrahami, A. Douros, H. Yin, O.H. Yu, J.L. Faillie, F. Montastruc, R.W. Platt, N. Bouganim, L. Azoulay, Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 363, k4880 (2018). https://doi.org/10.1136/bmj.k4880 CrossRefPubMedPubMedCentral

59.

D. Abrahami, H. Yin, O.H.Y. Yu, M.N. Pollak, L. Azoulay, Incretin-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes. Epidemiology 29(2), 246–253 (2018). https://doi.org/10.1097/EDE.0000000000000793 CrossRefPubMed

60.

B.M. Hicks, H. Yin, O.H. Yu, M.N. Pollak, R.W. Platt, L. Azoulay, Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. BMJ 355, i5340 (2016). https://doi.org/10.1136/bmj.i5340 CrossRefPubMed

61.

H. Zhao, R. Wei, L. Wang, Q. Tian, M. Tao, J. Ke, Y. Liu, W. Hou, L. Zhang, J. Yang, T. Hong, Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. Am. J. Physiol. Endocrinol. Metab. 306(12), E1431–E1441 (2014). https://doi.org/10.1152/ajpendo.00017.2014 CrossRefPubMed

62.

R. Gentilella, V. Pechtner, A. Corcos, A. Consoli, Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Diabetes Metab. Res Rev. 35(1), e3070 (2019). https://doi.org/10.1002/dmrr.3070 CrossRefPubMed

Title: GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials
Authors: Chuqing Cao
Shuting Yang
Zhiguang Zhou
Publication date: 01-11-2019
Publisher: Springer US
Keywords: Albiglutide
Exenatide
Diabetes
Incretin Mimetics
Incretin Mimetics
Type 2 Diabetes
Pancreatic Cancer
Pancreatic Cancer
Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: Endocrine / Issue 2/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-02055-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patients

In early pubertal boys, testosterone and LH are associated with improved anti-oxidation during an aerobic exercise bout

Effect of 9 months of vitamin D supplementation on arterial stiffness and blood pressure in Graves’ disease: a randomized clinical trial

Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study

Hypothyroidism-related zinc deficiency leads to suppression of T lymphocyte activity

The utility of adrenal and ovarian venous sampling in a progesterone-producing adrenal tumor and review of the literature

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page